Driven by expensive drugs, hospital stays and growing behavioral health needs, healthcare spending is expected to keep rising ...

Elevidys is a gene therapy approved to treat Duchenne muscular dystrophy. Last month, Sarapta halted sales of the therapy for non-ambulatory patients.

The high cost of pharmaceutical products coupled with a lack of federally funded HIV programs create barriers for preexposure prophylaxis (PrEP) access according to Jeremiah Johnson, executive ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

Switching to extended half-life therapies for hemophilia enhances treatment adherence and reduces infusion frequency, despite ...

H. pylori infection significantly contributes to stomach cancer risk, but effective screening and treatment can prevent ...

A panelist discusses how the FDA approval and NCCN endorsement of retifanlimab plus carboplatin/paclitaxel represents a ...

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

An expert discusses how patients with vitiligo are often initially misdiagnosed by primary care providers as having fungal ...

Autoimmune diseases, such as vitiligo, celiac disease and rheumatoid arthritis, are not tied to aluminum exposure from vaccines, according to a nationwide cohort study of approximately 1.2 million ...

The combination of RPI, a genetically engineered herpes simplex virus type 1, and Opdivo shrank both injected and non-injected tumors by 30%.

Mulugeta Gebregziabher, Ph.D., spoke with Managed Healthcare Executive ahead of his presentation at IAS 2025 in Kigali, ...